Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Publication/Presentation Date
2016
Volume
132
Issue
1
First Page
154
Last Page
154
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Fellows and Residents
Document Type
Article
COinS